Remove 2016 Remove FDA Approval Remove Pharmacokinetics Remove Trials
article thumbnail

Analysis Life Sciences Thank You FDA’s nonprescription advisors find no efficacy for phenylephrine

Agency IQ

Until recently, the FDA relied on a monograph process through which firms could bring OTC drugs to market without FDA approval so long as it adhered to pre-set terms under the monograph. Finally, the committee came up with a list of recommendations for the structure of additional trials, listed in the meeting minutes.

Science 40
article thumbnail

Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints.

The Pharma Data

Results reinforce well-established safety profile of Dupixent – the first ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old. The trial demonstrated similar safety results to the known safety profile of Dupixent in atopic dermatitis. In 2016, the U.S. Yancopoulos, M.D.,

Trials 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Improving quality control for CAR T cell therapies

Drug Discovery World

Finally, in 2017, after years of improving T cell engineering techniques, the first chimeric antigen receptor (CAR) T cell therapy received FDA approval. Since 2017, five CAR T cell therapies have been approved and have shown incredible success in the clinic. Measuring the pharmacokinetics of CAR T cells. 2018) 18(1).

Therapies 246
article thumbnail

FDA for approval to treat VTE and to prevent VTE in children

The Pharma Data

There are currently no FDA-approved anticoagulation therapies for pediatric patients with congenital heart disease who have undergone the Fontan procedure. From November 2016 to June 2019, a total of 112 participants were enrolled across 36 sites in 10 countries. EINSTEIN-Jr. About the EINSTEIN-Jr.

FDA 52
article thumbnail

Advances in the Battle Against Autoimmune Disease

The Pharma Data

SetPoint Medical received FDA Investigational Device Exemption (IDE) approval for a multicenter, double-blind, randomized, sham-controlled pivotal trial that will enroll up to 250 patients at 40 clinical trial sites in the U.S. The secondary outcome involves pharmacokinetic endpoints. Small Molecule Inhibitors.

Disease 52